KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Assets: 2009-2025

Historic Return on Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 0.28%.

  • Halozyme Therapeutics' Return on Assets rose 9.00% to 0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.28%, marking a year-over-year increase of 9.00%. This contributed to the annual value of 0.23% for FY2024, which is 8.00% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Return on Assets stood at 0.28%, which was up 6.24% from 0.26% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Return on Assets high stood at 0.38% for Q1 2022, and its period low was 0.10% during Q1 2023.
  • In the last 3 years, Halozyme Therapeutics' Return on Assets had a median value of 0.18% in 2024 and averaged 0.19%.
  • As far as peak fluctuations go, Halozyme Therapeutics' Return on Assets skyrocketed by 36bps in 2021, and later fell by 28bps in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Return on Assets (Quarterly) stood at 0.35% in 2021, then declined by 24bps to 0.11% in 2022, then increased by 5bps to 0.16% in 2023, then climbed by 6bps to 0.21% in 2024, then increased by 9bps to 0.28% in 2025.
  • Its Return on Assets stands at 0.28% for Q3 2025, versus 0.26% for Q2 2025 and 0.23% for Q1 2025.